PeptideComparePramlintide — EU research guide.
Pramlintide is a synthetic analogue of amylin, the pancreatic hormone that slows gastric emptying and blunts post-meal glucagon — the same target class as cagrilintide, but first to reach the clinic decades earlier.
What is Pramlintide?
Pramlintide mimics amylin, a hormone co-secreted with insulin that beta cells release after meals. It slows gastric emptying, reduces glucagon secretion and increases satiety — complementary to, rather than overlapping with, GLP-1 agonism.
Status and research context
Approved in the US as Symlin for insulin-treated diabetes since 2005, pramlintide is listed as discontinued in some US drug databases but not in others, and no EU marketing authorisation was found. Its mechanism directly informs newer, longer-acting amylin analogues such as cagrilintide and petrelintide, now in Phase 3 obesity trials.
EU legal status
No EU marketing authorisation was found; US market status is reported inconsistently. Research-grade pramlintide is available from RUO peptide suppliers.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ Modelled per compound from molecular structure — chain length, cyclisation, oxidation- and deamidation-prone residues and light sensitivity. Indicative only, not lab-measured per batch.
Amylin-class compounds across EU suppliers
COA-verified EU vendors · Updated monthly
References
- The official US label (revised February 2015): indication as an add-on to mealtime insulin, boxed warning for severe hypoglycaemia, half-life of about 48 minutes in healthy people, storage (refrigerated, not frozen, away from light) and the pooled 6-month trial results. This is the licensed product, not vendor 'research' vials. SYMLIN (pramlintide acetate) injection: US prescribing information. US Food and Drug Administration; revised February 2015. Source
- The peer-reviewed 1-year trial in type 2 diabetes: 656 randomised participants on insulin, placebo-controlled. It shows lower HbA1c and weight with pramlintide and nausea as the main side effect; it is manufacturer-linked research and does not cover outcomes such as complications. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784-790. DOIPubMed 12610038
- The peer-reviewed 1-year trial in type 1 diabetes. The title reports better long-term glycaemic and weight control with pramlintide added to insulin; the size of the effect is small, and the figures in this guide come from a later review of the trial. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204-1212. DOIPubMed 15498087
- A clinical review of type 1 and type 2 trials lasting 4 to 52 weeks. It confirms modest HbA1c reductions and names nausea and hypoglycaemia as the main adverse events; it is a secondary source from the period of approval. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther. 2005;27(10):1500-1512. DOIPubMed 16330288
- A review of amylin physiology and pramlintide. It explains why the molecule was engineered with three proline substitutions (native amylin is unstable in solution) and summarises the 1-year type 1 trial figures; it is a review, not a new trial. Hoogwerf BJ, Doshi KB, Diab D. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc Health Risk Manag. 2008;4(2):355-362. Source